Author Held, Gerhard

1 to 20 of 44 Items
  • 2023 | Journal Article
    ​ ​Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP​
    Bewarder, M.; Kaddu-Mulindwa, D.; Kos, I. A.; Lesan, V.; Held, G.; Poeschel, V. & Thurner, L. et al.​ (2023) 
    Haematologica,.​ DOI: https://doi.org/10.3324/haematol.2022.282126 
    ​Details  DOI 
  • 2023 | Journal Article
    ​ ​Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study​
    Thurner, L.; Ziepert, M.; Berdel, C.; Schmidt, C.; Borchmann, P.; Kaddu-Mulindwa, D. & Viardot, A. et al.​ (2023) 
    HemaSphere, 7(7) art. e904​.​ DOI: https://doi.org/10.1097/HS9.0000000000000904 
    ​Details  DOI 
  • 2023 | Journal Article
    ​ ​Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial​
    Held, G.; Thurner, L.; Poeschel, V.; Ott, G.; Schmidt, C.; Christofyllakis, K. & Viardot, A. et al.​ (2023) 
    HemaSphere, 7(7) art. e917​.​ DOI: https://doi.org/10.1097/HS9.0000000000000917 
    ​Details  DOI 
  • 2022 | Journal Article
    ​ ​KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials​
    Kaddu-Mulindwa, D.; Altmann, B.; Robrecht, S.; Ziepert, M.; Regitz, E.; Tausch, E. & Held, G. et al.​ (2022) 
    The Lancet Haematology, 9(2) pp. e133​-e142​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00369-0 
    ​Details  DOI 
  • 2021 | Journal Article
    ​ ​Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial​
    Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Haenel, M. & Truemper, L. et al.​ (2021) 
    The Lancet Haematology, 8(4) pp. e267​-e277​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00022-3 
    ​Details  DOI 
  • 2021 | Journal Article | Research Paper
    ​ ​Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma​
    Nordmo, C.; Glehr, G.; Altenbuchinger, M. ; Spang, R.; Ziepert, M.; Horn, H. & Staiger, A. M. et al.​ (2021) 
    Leukemia & Lymphoma, 62(5) pp. 1107​-1115​.​ DOI: https://doi.org/10.1080/10428194.2020.1861268 
    ​Details  DOI  PMID  PMC 
  • 2020 | Journal Article
    ​ ​Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial​
    Wulf, G. G. ; Altmann, B.; Ziepert, M.; D’Amore, F.; Held, G.; Greil, R. & Tournilhac, O. et al.​ (2020) 
    Leukemia,.​ DOI: https://doi.org/10.1038/s41375-020-0838-5 
    ​Details  DOI 
  • 2020 | Journal Article | Research Paper | 
    ​ ​Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group​
    Høhloch, K. ; Ziepert, M.; Trümper, L. ; Buske, C.; Held, G.; Poeschel, V. & Chapuy, B.  et al.​ (2020) 
    eJHaem, 1(1) pp. 181​-187​.​ DOI: https://doi.org/10.1002/jha2.61 
    ​Details  DOI 
  • 2020 | Journal Article | 
    ​ ​Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)​
    Zettl, F.; Ziepert, M.; Altmann, B.; Zeynalova, S.; Held, G.; Pöschel, V. & Hohloch, K.  et al.​ (2020) 
    Annals of Hematology, 100(4) pp. 1031​-1038​.​ DOI: https://doi.org/10.1007/s00277-020-04345-3 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD​
    Schlenk, R. F.; Weber, D.; Fiedler, W.; Salih, H. R.; Wulf, G. ; Salwender, H. & Schroeder, T. et al.​ (2019) 
    Blood, 133(8) pp. 840​-851​.​ DOI: https://doi.org/10.1182/blood-2018-08-869453 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial​
    Poeschel, V.; Held, G.; Ziepert, M.; Witzens-Harig, M.; Holte, H.; Thurner, L. & Borchmann, P. et al.​ (2019) 
    The Lancet, 394(10216) pp. 2271​-2281​.​ DOI: https://doi.org/10.1016/S0140-6736(19)33008-9 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL​
    Staiger, A. M.; Altenbuchinger, M. ; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Hüttl, K. S. et al.​ (2019) 
    Leukemia, 34(2) pp. 543​-552​.​ DOI: https://doi.org/10.1038/s41375-019-0573-y 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study​
    Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Hänel, M. & Truemper, L. et al.​ (2019) 
    Blood, 134(Supplement_1) pp. 1589​-1589​.​ DOI: https://doi.org/10.1182/blood-2019-123637 
    ​Details  DOI 
  • 2018 | Journal Article
    ​ ​Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease​
    Wulf, G. ; Hasenkamp, J. ; Jung, W. ; Wilhelm, C.; Held, G.; Nickelsen, M. & Leha, A.  et al.​ (2018) 
    Bone Marrow Transplantation, 54(6) pp. 877​-884​.​ DOI: https://doi.org/10.1038/s41409-018-0360-9 
    ​Details  DOI 
  • 2018 | Journal Article
    ​ ​A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group​
    Staiger, A. M.; Altenbuchinger, M.; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Huettl, K. et al.​ (2018) 
    Blood, 132(Supplement 1) pp. 343​-343​.​ DOI: https://doi.org/10.1182/blood-2018-99-112450 
    ​Details  DOI 
  • 2018 | Journal Article
    ​ ​Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.​
    Pfreundschuh, M.; Murawski, N.; Ziepert, M.; Altmann, B.; Dreyling, M. H.; Borchmann, P. & Luminari, S. et al.​ (2018) 
    Journal of Clinical Oncology, 36(15_suppl) pp. 7574​-7574​.​ DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.7574 
    ​Details  DOI 
  • 2018 | Journal Article
    ​ ​Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA​
    Poeschel, V.; Held, G.; Ziepert, M.; Altmann, B.; Witzens-Harig, M.; Holte, H. & Thurner, L. et al.​ (2018) 
    Blood, 132(Supplement 1) pp. 781​-781​.​ DOI: https://doi.org/10.1182/blood-2018-99-112403 
    ​Details  DOI 
  • 2017 | Journal Article
    ​ ​Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.​
    Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
    Journal of Clinical Oncology, 35(15_suppl) pp. 7539​-7539​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7539 
    ​Details  DOI 
  • 2017 | Journal Article
    ​ ​Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.​
    Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
    Journal of Clinical Oncology, 35(15_suppl) pp. 7506​-7506​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7506 
    ​Details  DOI 
  • 2017 | Journal Article
    ​ ​Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients​
    Pfreundschuh, M.; Murawski, N.; Zeynalova, S.; Ziepert, M.; Loeffler, M.; Hänel, M. & Dierlamm, J. et al.​ (2017) 
    British Journal of Haematology, 179(3) pp. 410​-420​.​ DOI: https://doi.org/10.1111/bjh.14860 
    ​Details  DOI 

Researcher

Göttingen All

Sort

issue date

ASC DESC

Items per Page

10 20 50 100